Related Experiment Videos
Effect of immediate hemoglobin A1c results on treatment decisions in office practice
A Ferenczi1, K Reddy, D L Lorber
1New York Hospital Medical Center of Queens, Flushing, New York 11365, USA.
Insights
Immediate hemoglobin A1c (HbA1c) testing significantly improves glycemic control in type 2 diabetes patients. Rapid results empower physicians to make timely treatment decisions, leading to better patient outcomes.
Area of Science:
- Endocrinology
- Diabetes Management
- Clinical Practice
Background:
- Type 2 diabetes management requires regular monitoring of glycemic control.
- Hemoglobin A1c (HbA1c) is a key indicator of long-term blood glucose levels.
- Timely access to HbA1c results can influence clinical decision-making.
Purpose of the Study:
- To evaluate the impact of immediately available HbA1c results on glycemic control.
- To assess how rapid HbA1c availability affects physician decisions regarding pharmacologic therapy.
- To compare outcomes between patients with immediate vs. delayed HbA1c results.
Main Methods:
- Retrospective review of medical records for 115 elderly patients with type 2 diabetes.
- Comparison of two groups: immediate HbA1c results (Group A) vs. delayed results (Group B).
- Analysis of HbA1c level changes over 12 months and treatment modifications.
Main Results:
- Group A (immediate results) showed a mean HbA1c decrease of 1.03%, versus 0.33% in Group B (delayed results).
- Pharmacologic treatment interventions occurred in 52% of Group A patients during the first visit, compared to 27% in Group B.
- Improved glycemic control was observed in patients receiving immediate HbA1c feedback.
Conclusions:
- Immediate availability of HbA1c results enhances physician's therapeutic decision-making.
- Rapid HbA1c feedback leads to improved glycemic control in type 2 diabetes patients.
- Office-based practices benefit from point-of-care HbA1c testing for better diabetes management.
Objective:
To assess the effect of an immediately available hemoglobin A1c (HbA1c) result on glycemic control and physician decisions about pharmacologic therapy in an office practice.
Methods:
In a 1-year retrospective review of medical records, HbA1c results were analyzed in 115 patients beyond the age of 65 years, who had type 2 diabetes and were referred for the first time to a private endocrinology practice between April 1, 1997, and March 31, 1998. These patients were classified into two groups: group A (N = 93, insured by standard Medicare) had immediate HbA1c results (during the patient encounter) and group B (N = 22, insured by Medicare health maintenance organization [HMO]) had commercial laboratory HbA1c results available within 2 to 3 days. We reviewed the changes in the HbA1c level during the 12-month period and the presence or absence of a change in therapy at each visit. HbA1c levels were measured by ion-exchange low-pressure liquid chromatography in group A and by one of three capitated commercial laboratories (depending on HMO contracts) in group B.
Results:
At the end of the 12 months, the mean HbA1c decrease was 1.03 +/- 0.33% in group A and 0.33 +/- 0.83% in group B. During the first visit, 52% of the patients in group A had pharmacologic treatment interventions, whereas only 27% in group B had such interventions.
Conclusion:
Rapid availability of the HbA1c results during the clinical encounter improves the ability of the physician to make appropriate therapeutic decisions and results in improved glycemic control.